SLC5A2 and atherosclerosis: Recent animal studies have demonstrated that treatment with SGLT2 inhibitors can reduce oxidative stress and the inflammation processes that are closely associated with and essential to the genesis of endothelial dysfunction and atherosclerosis [53–55].